Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs

About a year after launching a prior round of layoffs, Coherus BioSciences is again reducing its head count, this time by 30%.

Coherus unveiled the latest job cuts Wednesday alongside its full-year 2023 financial results. The company was previously left with about 300 employees after a reduction last March forced 60 staffers out of the door.